MX2018005876A - Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. - Google Patents

Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.

Info

Publication number
MX2018005876A
MX2018005876A MX2018005876A MX2018005876A MX2018005876A MX 2018005876 A MX2018005876 A MX 2018005876A MX 2018005876 A MX2018005876 A MX 2018005876A MX 2018005876 A MX2018005876 A MX 2018005876A MX 2018005876 A MX2018005876 A MX 2018005876A
Authority
MX
Mexico
Prior art keywords
plasminogen
wound healing
dosage regimen
dose
once
Prior art date
Application number
MX2018005876A
Other languages
English (en)
Spanish (es)
Inventor
Bertheim Ulf
Ny Tor
Laurin Pierre
Robitaille Martin
Original Assignee
Prometic Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Ltd filed Critical Prometic Biotherapeutics Ltd
Publication of MX2018005876A publication Critical patent/MX2018005876A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2018005876A 2015-11-10 2016-11-10 Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. MX2018005876A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562253352P 2015-11-10 2015-11-10
PCT/IB2016/001606 WO2017081529A1 (en) 2015-11-10 2016-11-10 Plasminogen dosage regimen for wound healing

Publications (1)

Publication Number Publication Date
MX2018005876A true MX2018005876A (es) 2018-11-09

Family

ID=57485826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005876A MX2018005876A (es) 2015-11-10 2016-11-10 Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.

Country Status (14)

Country Link
US (1) US20180326023A1 (https=)
EP (1) EP3373957A1 (https=)
JP (1) JP2018534306A (https=)
KR (1) KR20180070708A (https=)
CN (1) CN108289934A (https=)
AU (1) AU2016352183A1 (https=)
BR (1) BR112018009476A8 (https=)
CA (1) CA3004509A1 (https=)
IL (1) IL259172A (https=)
MX (1) MX2018005876A (https=)
RU (1) RU2018121234A (https=)
TW (1) TW201722464A (https=)
WO (1) WO2017081529A1 (https=)
ZA (1) ZA201803010B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN111050763B (zh) * 2017-12-26 2024-10-11 福冈大太朗 用于増毛、头皮或皮肤的改质、创伤治愈、骨形成促进或毛发的改质的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
WO2009093970A1 (en) * 2008-01-22 2009-07-30 Omnio Healer Ab Method of improving wound healing
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法

Also Published As

Publication number Publication date
WO2017081529A1 (en) 2017-05-18
ZA201803010B (en) 2019-07-31
JP2018534306A (ja) 2018-11-22
BR112018009476A2 (pt) 2018-11-13
US20180326023A1 (en) 2018-11-15
CA3004509A1 (en) 2017-05-18
AU2016352183A1 (en) 2018-06-28
IL259172A (en) 2018-06-28
KR20180070708A (ko) 2018-06-26
EP3373957A1 (en) 2018-09-19
RU2018121234A3 (https=) 2020-03-12
RU2018121234A (ru) 2019-12-13
BR112018009476A8 (pt) 2019-02-26
TW201722464A (zh) 2017-07-01
CN108289934A (zh) 2018-07-17

Similar Documents

Publication Publication Date Title
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MY199903A (en) Combination therapy with controlled-release cnp agonists
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MY204827A (en) Semaglutide in medical therapy
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
IN2013MU01696A (https=)
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX383344B (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
NZ751972A (en) Treatment of prurigo nodularis
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
ZA201906153B (en) Pharmaceutical compositions for combination therapy
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
HK40048989A (en) Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
EP3813687A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF THROMBOSIS AND ADMINISTRATION THROUGH MEDICAL DEVICES